One day? Would they risk only 24 hours to kill the Virus? Once safety at 3 days passed the short test it made sense to move to 5...They'll have a few subjects with 3 and the rest 5...
"Is anyone else concerned that B (under the old Polymedix study) had more AEs when it was given at higher doses (and longer time?) with ABBSSSI?"
It has been discussed here a few times, but for some reason it's not a popular topic of conversation. Olden-grumpini and KMBJN had some sensible and informed discussion about it. You can see some of it here:
"When IPIX re-ran study I recall they reduced the dose (and ran for shorter time?). Maybe with COVID trial they should have experimented going from 3 days to 1 day dosing, rather than to 5 days?"
It's notable that they haven't said what daily dose they are using in the COVID-19 study.
My guess given the AE issue you mention is that they dialled down the mg/kg dose considerably, which is one reason they wanted to move from 3 to 5 days to increase exposure of virus to drug in terms of AUC (area under the curve) hoping that would make up for a lower peak concentration that risks missing the MIC (minimum inhibitory concentration).
News 
Market Data 
Discover 
